Projektinformation

Beskrivning

Genetically modified T cells have shown unprecedented success in infant and pediatric relapsed and/or refractory (r/r) acute lymphoblastic leukemia (ALL) when relying on lineage-restricted antigens. Unfortunately, similar responses have proven ineffective in myeloid malignancies, e.g. acute myeloid leukemia (AML), largely due to the lack of truly tumor-specific antigens. This proposal builds on state-of-the-art synthetic biological tools to empower engineered T cells to enable safer targeting of AML cells
StatusPågående
Gällande start-/slutdatum2023/06/012027/05/31

Finansiering

  • Barncancerfonden